Phase III PEMPHIX study showed that Roche ’s Mabthera/Rituxan (rituximab) is superior to standard of care in achieving sustained remission in patients with pemphigus vulgaris
Roche today announced positive topline results from the Roche-sponsored phase III PEMPHIX study, evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). (Source: Roche Investor Update)
Source: Roche Investor Update - June 13, 2019 Category: Pharmaceuticals Source Type: news
Hailey-Hailey Disease (Familial Benign Pemphigus)
Title: Hailey-Hailey Disease (Familial Benign Pemphigus)Category: Diseases and ConditionsCreated: 5/15/2019 12:00:00 AMLast Editorial Review: 5/17/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - May 17, 2019 Category: Dermatology Source Type: news
European Commission approves Roche ’s MabThera (rituximab) for a rare autoimmune disease
Roche today announced that the European Commission has approved MabThera ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterised by progressive painful blistering of the skin and/or mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - March 15, 2019 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s MabThera (rituximab) for a rare autoimmune disease
Roche today announced that the European Commission has approved MabThera ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterised by progressive painful blistering of the skin and/or mucous membranes. (Source: Roche Media News)
Source: Roche Media News - March 15, 2019 Category: Pharmaceuticals Source Type: news
Durable Urticaria Control With Anti-IgE Drug
(MedPage Today) -- BTK inhibitor for pemphigus, anti-IL-36 drug for pustular psoriasis show early promise at AAD (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 7, 2019 Category: Primary Care Source Type: news
Pemphigus Vulgaris as Manifestation of Multiple Myeloma Pemphigus Vulgaris as Manifestation of Multiple Myeloma
This case illustrates an uncommon occurrence of multiple myeloma initially presenting with pemphigus vulgaris.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
FDA approves Roche ’s MabThera/Rituxan (rituximab) for pemphigus vulgaris
Roche announced today that the US Food and Drug Administration (FDA) has approved MabThera/Rituxan ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - June 8, 2018 Category: Pharmaceuticals Source Type: news
Deadly Skin Disorder Gets First New Drug in 60 Years
(MedPage Today) -- FDA approves rituximab (Rituxan) for pemphigus vulgaris (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - June 8, 2018 Category: Dermatology Source Type: news
FDA Approves Genentech ’s Rituxan (rituximab) for Pemphigus Vulgaris
South San Francisco, CA -- June 7, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 7, 2018 Category: Drugs & Pharmacology Source Type: news
Treatment Refractoriness of Oral Lesions in Pemphigus Vulgaris Treatment Refractoriness of Oral Lesions in Pemphigus Vulgaris
Oral lesions in patients with pemphigus vulgaris are often more treatment refractory than skin lesions. What clinical and laboratory parameters might be useful in determining lesion prognosis?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 28, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
FDA grants priority review for Roche ’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris
Roche announced today that the US Food and Drug Administration (FDA) has accepted the company ’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of MabThera/Rituxan® (Rituximab) for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - February 14, 2018 Category: Pharmaceuticals Source Type: news
Guidelines for the Management of Pemphigus Vulgaris 2017 Guidelines for the Management of Pemphigus Vulgaris 2017
The British Association of Dermatologists presents updated, evidence-based guidelines for the management of pemphigus vulgaris, with recommendations for practical use in the clinic.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
argenx initiates Phase II trial of ARGX-113 to treat pemphigus vulgaris
Belgium-based biotechnology firm argenx has initiated a Phase II clinical trial of its investigational agent, ARGX-113, to treat patients with pemphigus vulgaris (PV). (Source: Drug Development Technology)
Source: Drug Development Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news
Medical News Today: Pemphigus foliaceus: Symptoms, diagnosis, and treatment
In this article, learn about pemphigus foliaceus. What is pemphigus foliaceus, what causes pemphigus foliaceus and how is it diagnosed? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 31, 2017 Category: Consumer Health News Tags: Dermatology Source Type: news
